Financials data is unavailable for this security.
Inc stmt in DKKIncome statement in DKK
Year on year
Novo Nordisk A/S grew revenues 4.04% from 122.02bn to 126.95bn while net income improved 8.18% from 38.95bn to 42.14bn.
|Net profit margin||34.31%|
|Return on assets||29.41%|
|Return on equity||73.49%|
|Return on investment||59.69%|
Cash flow in DKK
In 2020, cash reserves at
Novo Nordisk A/S fell by 3.19bn. However, the company earned 51.95bn from its operations for a Cash Flow Margin of 40.92%. In addition the company used 22.44bn on investing activities and also paid 32.24bn in financing cash flows.
|Cash flow per share||22.29|
|Price/Cash flow per share||22.19|
|Book value per share||29.10|
|Tangible book value per share||20.06|
Balance sheet in DKK
|Total debt/total equity||0.208|
|Total debt/total capital||0.1722|
Growth rates in DKK
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.98% and 9.97%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
|Div yield(5 year avg)||2.47%|
|Div growth rate (5 year)||7.29%|
|Payout ratio (TTM)||35.64%|
|EPS growth(5 years)||5.89|
|EPS (TTM) vs |
TTM 1 year ago